---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-23-006974"
form_type: "8-K"
ticker: "ANEB"
cik: "0001815974"
company_name: "Anebulo Pharmaceuticals, Inc."
filed_at: "2023-03-08T23:59:59+00:00"
generated_at: "2026-06-18T08:41:12.464433+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Anebulo appoints Sandra A. Gardiner as Acting CFO via Potrero Hill Advisors agreement

## Summary
- Sandra A. Gardiner appointed Acting CFO, principal financial and accounting officer effective March 2, 2023.
- Gardiner replaces Rex Merchant; she will provide services through Master Services Agreement with Potrero Hill Advisors.
- Gardiner previously served as CFO of Pulse Biosciences (Nasdaq: PLSE) and Cutera, Inc.
- Master Services Agreement has five-year term, hourly rate compensation with annual 5% increase option, and 30-day termination notice.
- No direct agreement between Company and Gardiner; all terms governed by the consulting arrangement.

## SEC filing metadata
- accession: 0001493152-23-006974
- form_type: 8-K
- ticker: ANEB
- cik: 0001815974
- company_name: Anebulo Pharmaceuticals, Inc.
- filed_at: 2023-03-08T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 1.01, 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1815974/000149315223006974/0001493152-23-006974-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1815974/000149315223006974/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-23-006974
- JSON: https://secwatch.observer/filing/0001493152-23-006974.json
- Plain text: https://secwatch.observer/filing/0001493152-23-006974.txt

## Key facts
- Executive change
  Sandra A. Gardiner was appointed as Acting Chief Financial Officer at Anebulo Pharmaceuticals, Inc..
  - Action: appointed
  - Role: Acting Chief Financial Officer
  source text: On March 2, 2023, the Company appointed Sandra A. Gardiner as the Company’s Acting Chief Financial Officer, as well as the Company’s principal financial officer and principal accounting officer, replacing Rex Merchant in such capacities.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1815974/000149315223006974/0001493152-23-006974-index.htm
- Executive change
  Rex Merchant departed as Chief Financial Officer at Anebulo Pharmaceuticals, Inc..
  - Role: Chief Financial Officer
  source text: replacing Rex Merchant in such capacities.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1815974/000149315223006974/0001493152-23-006974-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.